Repligen Corp (NASDAQ:RGEN)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.


Player Avatar zzlangerhans (99.85) Submitted: 12/18/2009 1:07:03 AM : Outperform Start Price: $3.79 RGEN Score: +7.52

Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 20% haircut on a stock already down 15% from recent highs. The company will likely continue to maintain cash flows even through anemic 5M quarterly revenues and lazy spending on the phase IIb trial of (yawn) uridine for bipolar disorder. Is this the most boring baby biotech around? Possibly. So why am I still writing this pitch? Trying to think of a reason why this stock will go back up. OK, because it did before. Wannafightaboudit?

Report this Post 2 Replies
Member Avatar zzlangerhans (99.85) Submitted: 5/28/2010 10:58:49 AM
Recs: 0

Just sold the 5000 shares I bought on 5/11 at 3.25 ( for 3.63. GBMB profit of $1900.

Member Avatar zzlangerhans (99.85) Submitted: 5/28/2010 11:01:23 AM
Recs: 0

Let me try that link once more:

Featured Broker Partners